BidaskClub Lowers Momenta Pharmaceuticals (NASDAQ:MNTA) to Strong Sell

BidaskClub downgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a sell rating to a strong sell rating in a research report released on Tuesday, BidAskClub reports.

Several other research analysts have also recently weighed in on MNTA. BTIG Research restated a buy rating on shares of Helius Medical Technologies in a research report on Monday, March 18th. Cantor Fitzgerald restated a buy rating and issued a $25.00 price objective on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. Finally, Zacks Investment Research cut shares of Farmers & Merchants Bancorp, Inc. (OH) from a hold rating to a strong sell rating in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $22.23.

MNTA stock opened at $10.88 on Tuesday. The stock has a 50 day moving average of $12.10. Momenta Pharmaceuticals has a fifty-two week low of $9.55 and a fifty-two week high of $32.20.



Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.01). Momenta Pharmaceuticals had a negative return on equity of 43.98% and a negative net margin of 231.49%. The company had revenue of $4.11 million during the quarter, compared to the consensus estimate of $10.12 million. During the same quarter last year, the firm earned ($0.63) EPS. The business’s revenue for the quarter was down 15.3% on a year-over-year basis. On average, analysts expect that Momenta Pharmaceuticals will post -1.79 earnings per share for the current fiscal year.

In other Momenta Pharmaceuticals news, SVP Santiago Arroyo sold 2,531 shares of the company’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $15.00, for a total transaction of $37,965.00. Following the completion of the sale, the senior vice president now owns 19,272 shares in the company, valued at approximately $289,080. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jo Ann Beltramello sold 13,672 shares of the company’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $15.00, for a total transaction of $205,080.00. Following the sale, the insider now owns 68,494 shares of the company’s stock, valued at approximately $1,027,410. The disclosure for this sale can be found here. Insiders have sold a total of 63,784 shares of company stock valued at $868,941 in the last quarter. Corporate insiders own 3.40% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. FMR LLC raised its position in shares of Momenta Pharmaceuticals by 25.7% during the 4th quarter. FMR LLC now owns 14,770,728 shares of the biotechnology company’s stock valued at $163,069,000 after acquiring an additional 3,023,513 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Momenta Pharmaceuticals by 14.0% in the 4th quarter. BlackRock Inc. now owns 13,775,141 shares of the biotechnology company’s stock valued at $152,079,000 after buying an additional 1,694,797 shares during the period. Primecap Management Co. CA grew its holdings in shares of Momenta Pharmaceuticals by 0.8% in the 1st quarter. Primecap Management Co. CA now owns 3,080,660 shares of the biotechnology company’s stock valued at $44,762,000 after buying an additional 23,965 shares during the period. Perceptive Advisors LLC grew its holdings in shares of Momenta Pharmaceuticals by 11,435.8% in the 4th quarter. Perceptive Advisors LLC now owns 2,825,000 shares of the biotechnology company’s stock valued at $31,132,000 after buying an additional 2,800,511 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Momenta Pharmaceuticals by 31.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,598,642 shares of the biotechnology company’s stock valued at $28,689,000 after buying an additional 628,870 shares during the period. Institutional investors own 97.43% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.